An Open-label Safety, Tolerability, and Dose-range Finding Study of Nusinersen (ISIS 396443) in Participants With Spinal Muscular Atrophy (SMA)
NCT01494701
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
28
Enrollment
INDUSTRY
Sponsor class
Conditions
Spinal Muscular Atrophy
Interventions
DRUG:
nusinersen
Sponsor
Biogen